{
  "ADD_TRANSACTION": "Ajouter un enregistrement",
  "SEQUENCE_NUM": "fr_Sequence Number",
  "NEW":"Nouvelle",
  "EXISTING":"Existant",
  "DATE_SUBMITTED": "fr_Date Submitted (YYYY-MM-DD)",
  "SEQUENCE_DESCRIPT": "fr_Regulatory Transaction Description",
  "IS_ACTCHANGES": "fr_Same as Regulatory Activity Contact for this Submission?",
  "COMPANY_ID": "ID d'entreprise",
  "DOSSIER_ID": "Numéro de dossier",
  "DOSSIER_NAME": "fr_Dossier Name",
  "IS_ECTD": "fr_Is this an eCTD transaction?",
  "IS_SOLICITED": "Cette information est-elle sollicitée?",
  "SOLICITED_RQ": "Demandeur d’information sollicitée",
  "SOLICITED_RQ_OTHER": "fr_Other Requester Details",
  "REP_CONTACT_INFO": "fr_Main Contact Information",
  "PROJ_MANAGER_NAME": "Responsable de projet réglementaire, si connu",
  "DATED": "Daté",
  "START_DATE": "Date de début",
  "END_DATE": "Date de fin",
  "REG_ACTIVITY": "fr_Regulatory Activity",
  "REG_ACTIVITY_TYPE": "Type d'activité réglementaire",
  "SEQUENCE_TYPE": "Description de transactions de réglementation",
  "VERSION_NO": "Numéro de la version",
  "BRIEF_DESC": "Brève description",
  "BRIEF_DESC_CHANGE": "Brève description des modifications apportées",
  "ADMINISTRATIVE": "Administrative",
  "BENEFIT_RISK_ASSESS": "Benefit Risk Assessment",
  "CANCEL_LETTER": "Cancellation Letter",
  "CHANGE_TO_DIN": "Change to DIN",
  "COMMENTS_NOC": "Comments on Notice of Decision",
  "COMMENTS_SUMMARY_BASIS": "Comments on Summary Basis of Decision (SBD)",
  "COMMENTS_REGULARTORY_DECISION": "Comments on Regulatory Decision Summary",
  "DIN_DISCONTINUED": "Notification of Discontinued Sale (DIN Cancellation)",
  "DRUG_NOTIF_FORM": "Drug Notification Form",
  "FOR_PERIOD": "For Period of",
  "INITIAL": "INITIAL",
  "MEETING_MINUTES": "Minutes of Meeting",
  "NOTIFICATION_CHANGE": "Notification of Change in Benefit-Risk Profile",
  "NOTIFICATION_INTERRUPT_SALE":"Notification Interruption of Sale",
  "PANDEMIC_APPL": "Pandemic Application",
  "POST_CLEARANCE_DATA": "Post Clearance Data",
  "POST_MARKET_SURV": "Post Marketing Surveillance",
  "POST_NOC_CHANGE": "Post NOC Change",
  "POST_AUTH_DIV1_CHANGE": "Post-Authorization Division 1 Change",
  "PRESUB_MEETING_PKG": "Submission Meeting Package",
  "PRESUB_MEETING_RQ": "Submission Meeting Request",
  "PRIORITY_REVIEW_RQ": "Priority Review Request",
  "PRISTINE_PM": "Pristine PM",
  "SECOND_LANG_PM": "Second Language PM",
  "PRISTINE_PM_2LANG": "Second Language PM and Final Package Insert",
  "ADVISEMENT_LETTER_RESPONSE": "Response to Advisement Letter",
  "CLIN_CLARIF_RESPONSE": "Response to Clinical Clarification Request",
  "EMAIL_RQ_RESPONSE": "Response to E-mail Request",
  "HSC_RQ_RESPONSE": "Response to Human Safety Clarification Request",
  "QHSC_RQ_RESPONSE": "Response to Quality & Human Safety Clarification Request",
  "CHSC_RQ_RESPONSE": "Response to Clinical & Human Safety Clarification Request",
  "QCHSC_RQ_RESPONSE": "Response to Quality, Clinical and Human Safety Clarification Request",
  "LABEL_CLARIF_RESPONSE": "Response to Labeling Clarification Request",
  "MHPD_RQ_RESPONSE": "Response to MHPD Request",
  "NOC_RESPONSE": "Response to NOC/c-QN",
  "NOD_RESPONSE": "Response to NOD",
  "NON_RESPONSE": "Response to NON",
  "NOL_RESPONSE": "Response to NOL",
  "PROCESSING_CLARIF_RESPONSE": "Response to Processing Clarification Request",
  "QUAL_CLIN_CLARIF_RESPONSE": "Response to Quality & Clinical Clarification Request",
  "QUAL_CLARIF_RESPONSE": "Response to Quality Clarification Request",
  "SCREENING_ACCEPT_RESPONSE": "Response to Screening Acceptance Letter",
  "SCREENING_CLARIF_RESPONSE": "Response to Screening Clarification Request",
  "SDN_RESPONSE": "Response to SDN",
  "PHONE_RQ_RESPONSE": "Response to Telephone Request",
  "RISK_COMMUN_DOC": "Risk Communication Document",
  "RMP_VERSION_DATE": "RMP",
  "SIGNAL_WORK_UP": "Signal Work Up",
  "UNSOLICITED_DATA": "Unsolicited Data",
  "YEAR_LIST_OF_CHANGE": "Year(s), list of change number(s)",
  "NONCLIN_CLARIF_RESPONSE": "Response to Non-clinical Clarification Request ",
  "BE_CLARIF_RESPONSE": "Response to BE Clarification Request",
  "RECON_DECIS_LTR_INTENT": "Reconsideration of Decision - Letter of Intent",
  "RECON_DECIS_RQ_RECON":  "Reconsideration of Decision - Request for Reconsideration",
  "RECON_DECIS_OTHER_INFO": "Reconsideration of Decision - Other Information",
  "LABEL_PREAPPROVAL_2LANG":"Second Language Label - Pre-Approval",
  "LIFECYCLE_TITLE": "Détails de la transaction",
  "REG_CONTACT_THIS": "Personne-ressource pour cette activité réglementaire",
  "REG_ACT_CONTACT": "fr_Regulatory Activity Contact",
  "TRANSACTION_HDING": "Information Réglementairen",
  "LOAD_TRANSACTION": "Charger un fichier de transaction réglemetaire",
  "COMPANY_INFO": "A. Information d'entreprise",
  "ADDRESS_INFO": "B. Information d'adresse",
  "COMPANY_REP_THIS": "C. Représentative de l'entrepise",
  "GENERATE_FINAL": "Générer le XML final",
  "CONFIRM_CONTACT_VALID": "Je confirme que l'information de la personne-ressource de l’activité réglementaire ci-dessus sont valides.",
  "YEAR_CHANGE": "Année(s) de changement, liste du/des numéro(s) de changement",
  "YEARS": "Année",
  "CTN_ADMINISTRATIVE": "CTN-Administrative Change to",
  "CTN_APPENDIX": "CTN-Appendix",
  "CTN_CONTACT": "CTN-Contact Change",
  "CTN_CROSS": "CTN-Cross Reference Letter",
  "CTN_DATA": "CTN-Data Safety Monitoring Committee",
  "CTN_DEAR": "CTN-Dear Investigator/Doctor Letter",
  "CTN_DILUENT": "CTN-Diluent Change",
  "CTN_DRUG_PROD": "CTN-Drug Product Change",
  "CTN_DRUG_SUBS": "CTN-Drug Substance change",
  "CTN_ENROLLMENT": "CTN-Enrollment Suspension",
  "CTN_ETHICS": "CTN-Ethics Board Communications",
  "CTN_EXCLUSION_INCLUSION": "CTN-Exclusion/Inclusion Criteria Revision",
  "CTN_INFORMED": "CTN-Informed Consent Form Update",
  "CTN_INVESTIGATOR": "CTN-Investigator’s Brochure Update",
  "CTN_NEW_MANUFACTURING": "CTN-New Manufacturing Site for",
  "CTN_NEW_PKG": "CTN-New Packaging/Labelling Site",
  "CTN_NEW_QC": "CTN-New QC Testing Site",
  "CTN_NOL": "CTN-NOL Response",
  "CTN_PACKAGING_LABELLING": "CTN-Packaging/Labelling Name Change",
  "CTN_PM": "CTN-PM Update",
  "CTN_PROTOCOL_INFO_UPDATE": "CTN-Protocol and Informed Consent Form Update",
  "CTN_PROTOCOL_UPDATE": "CTN-Protocol Update/Change",
  "CTN_QOS": "CTN-QOS Update",
  "CTN_REFUSALS": "CTN-Refusals by Foreign Regulatory Authorities/REBs",
  "CTN_REGULATORY": "CTN-Regulatory Hold",
  "CTN_RESPONSE": "CTN-Response to Information Request",
  "CTN_SAFETY": "CTN-Safety Update",
  "CTN_SHELF_PD": "CTN-Shelf Life Extension for DP",
  "CTN_SHELF_DS": "CTN-Shelf Life Extension for DS",
  "CTN_SITE": "CTN-Site Closure",
  "CTN_SOURCE": "CTN-Source Change of",
  "CTN_STRAIN": "CTN-Strain Change",
  "CTN_STUDY_COMPLETION": "CTN-Study Completion",
  "CTN_STUDY_DISC": "CTN-Study Discontinuation due to",
  "CTN_STUDY_EXT": "CTN-Study Recruitment Timeline Extension",
  "CTN_STUDY_SUS": "CTN-Study Suspension",
  "CTN_TRANS_OWN": "CTN-Transfer of Ownership",
  "CTN_FORM_BROC_UPDATES":"CTN-Informed Consent Form and Investigator’s Brochure Updates",
  "CTN_IMPD_UPDATE":"CTN-IMPD Update",
  "CTN_NEW_SUMM_ADF":"CTN-New Summary of Additional Drugs Form",
  "CLINICAL": "CLINICAL",
  "CLINICAL_QUALITY": "CLINICAL & QUALITY",
  "QUALITY": "QUALITY",
  "INITIAL_TEAT_SOLU_MONO":"INITIAL - Teat Solutions Monograph",
  "REQ_ACCEPTED":"Request Accepted",

  "REG_ACTIVITY_INSTRUCT":"Regulatory Activity Contact Instructions",
  "SAVE_INSTRUCT": "Transaction File Save Instructions",
  "CLARIF_RESPONSE":"Response to Clarification Request",
  "CORR_PATENT_MED":"Correspondence - Patented Medicines",
  "ALLEGATION_NOTICE":"Notice of Allegation",
  "FORM_IV":"Form IV",
  "FORM_V":"Form V",
  "CONSENT_LTR":"Consent Letter",
  "DATA_PROTECT_CORRESP":"Correspondence - Data Protection",
  "CHOOSE_REQUEST":"Choose a requester",
  "TRANSACT_INSTRUCT":"Regulatory Transaction Instructions",
  "LIST_DESCRIPT":"List Description",
  "SEQUENCE_CLEANUP":"eCTD Dossier Clean-up",
  "ADV_COMP_REQ": "Advertising Complaint Request for Information",
  "CSOtRMP": "Canadian Specific Opioid RMP",
  "DISSEM_LIST": "Dissemination List",
  "FOREIGN_SAFETY_NOTIFICATION": "Foreign Safety Action Notification",
  "ISSUE_SAFETY_REQUEST": "Issue Related Safety Request",
  "PATIENT_SAFETY_INFO": "Patient Safety Information (Medication error)",
  "PUB_RELEASE_INFO": "Public Release of Clinical Information",
  "RESSESS_ORDER": "Reassessment Order",
  "WRITTEN_CONSULT_REQ": "Request for Written Consultation",
  "TEST_STUDIES_ORDER": "Test and Studies Order",
  "TERM_COND_COMM": "Terms and Conditions Commitment",
  "YEAR": "Year",
  "REQUESTER_NAME":"Nom du demandeur",
  "REQUESTER_NAME2":"Nom du demandeur",
  "DEFER_FEES":" Un paiement différé est demandé avec cette transaction",
  "DEFER_STATEMENT":"La déclaration à l’appui de la demande de report de paiement est inclus.",
  "FEE_REMISSION":"Une remise de frais est demandé avec cette transaction",
  "STATEMENT_REVENUE":"Une déclaration signée par le responsable des affaires financières du demandeur est inclus pour attester que les frais payables sont plus élevés que 10% des revenus bruts anticipés.",
  "SUB_CLASS":"Catégorie de la présentation",
  "FEE_AMOUNT":"Frais",
  "FEE_DESCRIPTION":"Description de la présentation",
  "REMISSION_ELIGIBLE":"Vous êtes admissible à présenter une demande de remise des frais. Les frais de soumission sont supérieurs à 10 % des recettes brutes prévues.",
  "REMISSION_INELIGIBLE": "Vous n’êtes pas admissible à une remise des frais. Les frais de soumission sont inférieurs à 10 % des recettes brutes prévues.",
  "IS_FEE_TRANSACTION":"Est-ce que des frais nouveaux ou révisés sont-ils associés à cette transaction?",
  "REGULATORY_FEES":"Frais",
  "GROSS_REVENUE":"Les recettes brutes prévues pour ce médicament pour la période de vérification des frais payer",
  "TEN_PERCENT_REVENUE": "10% des recettes brutes prévues",
  "REQUIRED_DOC":"Documents nécéssaire",
  "SUPPORTING_DOC":"Veuillez inclure la déclaration exigée signée ET au moins un des documents de soutien pour l’établissement des frais applicables supérieurs à 10 % des revenus bruts prévus pour les ventes du produit au Canada au cours de la période de vérification.",
  "EST_MARKET_SHARE":"La part estimée du marché (c’est-à-dire le potentiel de marché du produit par rapport à la demande totale du marché pour des produits similaires au Canada)",
  "SIMILAR_PRODUCT":"Une comparaison avec des produits similaires offerts sur le marché canadien ou d’autres marchés similaires (par exemple États-Unis, Union européenne, etc.)",
  "SALES_HISTORY":"Un historique des ventes avant l’amélioration du produit ou un historique des ventes de produits similaires",
  "MARKETING_PLAN":"Un plan de marketing ou un plan de produit pour le produit pharmaceutique",
  "AVG_SALES":"Le prix de vente moyen et la demande",
  "FEES_LESS10K":"Des frais de 10 000 $ ou moins doivent être soumis au moment du dépôt de la présentation, le supplément ou la demande. S’il vous plaît remplir le formulaire Détails du paiement en avance pour présentations de drogues et fiches maîtresses.",
  "ADVANCE_PAYMENT":"Détails du paiement pour les présentations de drogue et les fiches maîtresses.",
  "SPONSOR_INVOICE":"Les frais d’examen ne doivent pas être inclus dans la présentation, le supplément à une présentation ou la demande de drogue. Les factures de plus de 10 000 $ seront envoyées aux promoteurs.",
  "PAYMENT_METHODS":"Veuillez sélectionner tous les modes de paiement que vous avez l’intention d’utiliser.",
  "ONE_PAYMENT_METHOD":"Veuillez sélectionner tous les modes de paiement que vous avez l’intention d’utiliser.",
  "ONE_FEE_DOC":"Au moins un des documents de soutien établissant que les frais applicables, supérieurs à 10 % des revenus bruts, sont prévus de la vente du produit au Canada au cours de la période de vérification.",
  "DEFER_INSTRUCT":"fr_Deferral of payment Instructions",
  "REMISSION_INSTRUCT":"fr_Fee remission Instructions",
  "CLASS_INSTRUCT":"fr_Submission Class Instructions",
  "PRODUCT_INSTRUCT":"fr_Product Name Instructions",
  "LIFECYCLE_INSTRUCT":"fr_Lifecycle Management Table Instructions",
  "SEQUENCE_INSTRUCT":"fr_Sequence Number Instructions",
  "CONTROL_INSTRUCT":"fr_Control Number Instructions",
  "COMPANY_INSTRUCT":"fr_Company Name Instructions",
  "COMPANY_ID_INSTRUCT":"fr_Company ID Instructions",
  "DOSSIER_ID_INSTRUCT":"fr_Dossier ID Instructions",
  "ADMIN_COMP_INSTRUCT": "fr_Administrative Submission or Component Instructions",
  "PLEASE_REMIT":"Veuillez payer les frais de traitement de la remise de 590$ en utilisant les détails du paiement en avance pour présentations de drogues et fiches maîtresses.",
  "APPLY_DEFER":"Vous demandez le report du paiement. Veuillez envoyer le présent formulaire sans aucun paiement.",
  "BANK_DRAFT":"Traite bancaire internationale",
  "MONEY_ORDER":"Mandat",
  "CHEQUE":"Chèque",
  "PAYMENT":"Paiement",
  "CREDIT":"MasterCard/Visa/American Express (AMEX)",
  "BANK_WIRE":"Transfert bancaire (incluez la confirmation de la banque)",
  "EXISTING_CREDIT":"Paiement au moyen d’un crédit existant",
  "PREFEERED_OPTION":"Option de service de paiement de factures (méthode préférée)",
  "REG_TRANSACT":"fr_Regulatory Transaction",
  "LIFE_REC":"Détails de l'enregistrement du transaction",
  "ONELIFEREC": "fr_One transaction details record is required.",
  "SAVELIFEREC": "Un enregistrement des détails de la transaction est nécessaire pour enregistrer.",
  "LIFECYCLECTRL.LIFECYCLEDETAILSFORM":"avec un ou plus des champs dans la section Détails de la transaction",
  "IS_NEW_ACTIVITY":"fr_Is this transaction for a new or existing regulatory activity?",
  "IS_SIGNED_3RD_PARTY": "La présentation sera-t-elle signée ou déposée par un tiers au nom du fabricant ou du promoteur?",
  "AUT_LETTER_NOTE": "Une lettre d’autorisation signée par le fabricant ou le promoteur doit être fournie à la section 1.2.1 de la transaction réglementaire.",
  "IS_PRIORITY":"Cette activité de réglementation a-t-elle été approuvée aux fins d’examen prioritaire?",
  "IS_NOC":"Cette activité de réglementation a-t-elle été approuvée aux fins d’examen AC-C? ",
  "IS_ADMIN_SUBMISSION": "Cette activité de réglementation est-elle une présentation administrative ou comprend-t-elle une composante administrative?",
  "ADMIN_DESCRIPT":"Description de la présentation administrative ou de la composante administrative",
  "ADMIN_SUB_TYPE":"Raison justifiant la présentation administrative ou la composante administrative",
  "ACTIVITY_LEAD": "Responsable de l’activité réglementaire",
  "OTHER_DOC_DETAILS": "Autres Détails de la Documentation",
  "B14-20160301-09":	"Pharmaceutique",
  "B14-20160301-02":	"Biologique",
  "B14-20160301-10":	"Vigilance après la commercialisation",
  "B14-20160301-06":	"Produit de santé destinés aux consommateurs",
  "B14-20160301-11":	"fr_Veterinary",
  "B14-20160301-04":	"fr_Clinical Trial - Biologics",
  "B14-20160301-05":	"fr_Clinical Trial - Pharmaceutical",
  "RESET": "Réinitialiser",
  "RESET_INFO" : "Si vous souhaitez activer le bouton « Générer le XML final », cliquez sur le bouton « Réinitialiser » pour effacer les renseignements spécifiques à la transaction.",
  "FEE_REMIT_NO_PAYMENT" :"fr_Please remit no payment with this transaction. Payment of the fees will be required upon issuance of an invoice",
  "MITIGATION_TYPE" : "fr_The following mitigation measures are available (select one). Sponsors must certify that they meet the criteria as outlined in the Food and Drug Regulations.",
  "CERTIFY_ORGANIZATION" : "fr_We certify that our organization, including its affiliates, has",
  "CERTIFY_ORGANIZATION_A" : "fr_a) a total number of employees less than 100 people, or",
  "CERTIFY_ORGANIZATION_B" : "fr_b) a total annual gross revenue between $30,000 and $5 million.",
  "SMALL_BUSINESS_FEE_APPLICATION":"fr_We have completed the Small Business Fee Mitigation Application and attached it with our submission/application.",
  "FIRST_SUBMISSION" : "fr_This is my first submission/application",
  "CERTIFY_GOVERMENT_ORGANIZATION" : "fr_We certify that our organization is a branch or agency of the Government of Canada or of a province or territory",
  "CERTIFY_URGENT_HEALTH_NEED":"fr_We certify that the drug in our submission/application is on the List of Drugs for an Urgent Public Health Need as per the Access to Drugs in Exceptional Circumstances Regulations AND",
  "DRUG_THE_SAME_INGREDIENT":"fr_a) the drug has the same medicinal ingredient, strength and route of administration, and is in a comparable dosage form, as a drug that may be imported under subsection C.10.001(2) of those Regulations;",
  "NO_DRUG_IDENTIFICATION_NUMBER":"fr_b) no drug identification number has been assigned under section C.01.014.2 of those Regulations for the drug or for another drug that has the same medicinal ingredient, strength and route of administration and is in a comparable dosage form; and",
  "NO_NOTICE_COMPLIANCE":"fr_c) no notice of compliance has been issued under section C.08.004 of those Regulations in respect of the drug or another drug that has the same medicinal ingredient, strength and route of administration and is in a comparable dosage form.",
  "CERTIFY_FUNDED_HEALTH_INSTITUTION":"fr_We certify that our institution is funded by the Government of Canada or the government of a province or territory and that it is",
  "CERTIFY_FUNDED_HEALTH_INSTITUTION_A":"fr_a) licensed, approved or designated by a province in accordance with the laws of the province to provide care or treatment to persons or animals suffering from any form of disease or illness; or",
  "CERTIFY_FUNDED_HEALTH_INSTITUTION_B":"fr_b) owned or operated by the Government of Canada or the government of a province and that provides health services.",
  "TYPE_MIN": "La date de fin ne doit pas être antérieure à la date de début.",
  "PROD_PROTOCOL": "fr_Protocol Number",
  "CTA_FROM": "fr_From [time]",
  "CTA_TO": "fr_To [time]",
  "COVIR-19": "Demande d'ordonnance provisoire COVID-19",
  "COVIR-19AMD": "Demande d'ordonnance provisoire COVID-19 - Modification"
}